Online citations, reference lists, and bibliographies.
← Back to Search

Clinical Studies With Anti-CTLA-4 Antibodies In Non-melanoma Indications.

L. Calabrò, R. Danielli, L. Sigalotti, M. Maio
Published 2010 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
Available medical treatments have limited impact on the survival of patients with advanced cancer; therefore, new therapeutic strategies able to generate more effective host's immune responses against neoplastic cells are being actively pursued. Among these, a recent approach involves targeting of cytotoxic T-lymphocyte antigen-4 (CTLA-4), a key immune checkpoint molecule, by monoclonal antibodies (mAbs). Ipilimumab and tremelimumab represent the prototypes of this new class of immunomodulating mAb and have been extensively tested in metastatic melanoma with highly promising results. The clinical activity observed in melanoma has served as a model to exploit the therapeutic potential of CTLA-4 blockade in a variety of human malignancies. Along this line, early-phase trials with anti-CTLA-4 mAbs have been completed or are ongoing in tumors of different histotype. Results are demonstrating the feasibility, safety, and activity of these agents, thus suggesting a promising therapeutic role to be further investigated in phase II/III trials in a wide range of tumors. This review summarizes the main trials with ipilimumab and tremelimumab in tumors of different histotypes, excluding cutaneous melanoma, which is extensively described in other chapters of this issue of Seminars in Oncology.
This paper references
10.1200/JCO.2010.28.3994
Phase II study of the anti-cytotoxic T-lymphocyte-associated antigen 4 monoclonal antibody, tremelimumab, in patients with refractory metastatic colorectal cancer.
K. Chung (2010)
10.1200/JCO.2010.28.15_SUPPL.4689
Final results of a phase I study of CTLA-4 blockade in combination with GM-CSF for metastatic castration resistant prostate cancer (mCRPC).
A. Harzstark (2010)
10.1158/1078-0432.CCR-09-1624
Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria
J. Wolchok (2009)
10.1158/1078-0432.CCR-10-0505
Tremelimumab in Combination with Exemestane in Patients with Advanced Breast Cancer and Treatment-Associated Modulation of Inducible Costimulator Expression on Patient T Cells
R. Vonderheide (2010)
10.1158/1078-0432.CCR-10-0569
Preoperative CTLA-4 Blockade: Tolerability and Immune Monitoring in the Setting of a Presurgical Clinical Trial
B. Carthon (2010)
10.1097/CJI.0b013e318156e47e
Ipilimumab (Anti-CTLA4 Antibody) Causes Regression of Metastatic Renal Cell Cancer Associated With Enteritis and Hypophysitis
J. Yang (2007)
10.1200/JCO.2008.26.15_SUPPL.5004
Phase I trial of ipilimumab (IPI) alone and in combination with radiotherapy (XRT) in patients with metastatic castration resistant prostate cancer (mCRPC)
T. Beer (2008)
10.1158/1078-0432.CCR-09-1339
Phase I Study of Ipilimumab, an Anti–CTLA-4 Monoclonal Antibody, in Patients with Relapsed and Refractory B-Cell Non–Hodgkin Lymphoma
S. Ansell (2009)
10.1200/JCO.2010.28.15_SUPPL.7531
Phase II trial of ipilimumab (IPI) and paclitaxel/carboplatin (P/C) in first-line stage IIIb/IV non-small cell lung cancer (NSCLC).
T. Lynch (2010)
10.1200/JCO.2006.24.18_SUPPL.2500
A dose-escalation trial of GM-CSF-gene transduced allogeneic prostate cancer cellular immunotherapy in combination with a fully human anti-CTLA antibody (MDX-010, ipilimumab) in patients with metastatic hormone-refractory prostate cancer (mHRPC).
W. Gerritsen (2006)
10.1016/S1359-6349(09)71959-7
9315 Ipilimumab in pretreated metastatic uveal melanoma patients: safety and clinical efficacy
R. Danielli (2009)
10.1200/jco.2009.27.15_suppl.8071
Randomized phase II clinical trial comparing tremelimumab (CP-675,206) with best supportive care (BSC) following first-line platinum-based therapy in patients (pts) with advanced non-small cell lung cancer (NSCLC).
P. Zatloukal (2009)
10.1200/JCO.2010.28.15_SUPPL.4134
A phase I dose escalation trial of CP-675206 (tremelimumab) in combination with gemcitabine in patients with chemotherapy-naive metastatic pancreatic cancer.
M. Aglietta (2010)
Ackerman's surgical pathology
L. V. Ackerman (1974)
10.1158/1078-0432.CCR-09-2376
Do We Need a Different Set of Response Assessment Criteria for Tumor Immunotherapy?
A. Ribas (2009)
10.1158/0008-5472.CAN-08-3529
Potentiating endogenous antitumor immunity to prostate cancer through combination immunotherapy with CTLA4 blockade and GM-CSF.
L. Fong (2009)
10.1097/JTO.0b013e3181ba2033
Prognostic Factors According to the Treatment Schedule in Malignant Pleural Mesothelioma
Guntulu Ak (2009)
10.1158/1078-0432.CCR-09-2870
Modulation of Lymphocyte Regulation for Cancer Therapy: A Phase II Trial of Tremelimumab in Advanced Gastric and Esophageal Adenocarcinoma
C. Ralph (2010)
10.1200/JCO.2006.24.18_SUPPL.4609
Randomized phase II study comparing 4 monthly doses of ipilimumab (MDX-010) as a single agent or in combination with a single dose of docetaxel in patients with hormone-refractory prostate cancer.
E. Small (2006)
10.1200/JCO.2010.28.15_SUPPL.2550
Overall survival (OS) analysis of a phase l trial of a vector-based vaccine (PSA-TRICOM) and ipilimumab (Ipi) in the treatment of metastatic castration-resistant prostate cancer (mCRPC).
R. Madan (2010)
10.1016/J.JURO.2010.02.1055
668 A RANDOMIZED PHASE II STUDY OF IPILIMUMAB WITH ANDROGEN ABLATION COMPARED WITH ANDROGEN ABLATION ALONE IN PATIENTS WITH ADVANCED PROSTATE CANCER
M. Tollefson (2010)
10.1158/1078-0432.CCR-06-2318
A Pilot Trial of CTLA-4 Blockade with Human Anti-CTLA-4 in Patients with Hormone-Refractory Prostate Cancer
E. Small (2007)
10.1200/JCO.2008.21.6432
Estrogen-progestagen menopausal hormone therapy and breast cancer: does delay from menopause onset to treatment initiation influence risks?
A. Fournier (2009)



This paper is referenced by
10.1007/s00011-012-0567-y
The effect of ionizing radiation on the homeostasis and functional integrity of murine splenic regulatory T cells
A. Balogh (2012)
10.1038/bjc.2012.361
Epigenetic remodelling of gene expression profiles of neoplastic and normal tissues: immunotherapeutic implications
S. Coral (2012)
10.1093/annonc/mds647
Rationale for targeting the immune system through checkpoint molecule blockade in the treatment of non-small-cell lung cancer
C. Zielinski (2013)
10.1097/MOU.0000000000000462
Prostate cancer immunotherapy: where are we and where are we going?
M. D. de Velasco (2018)
10.1186/bcr3035
A clinically relevant gene signature in triple negative and basal-like breast cancer
A. Rody (2011)
10.1001/jamaoncol.2018.6258
Efficacy and Safety of Avelumab for Patients With Recurrent or Refractory Ovarian Cancer: Phase 1b Results From the JAVELIN Solid Tumor Trial
M. Disis (2019)
10.1007/s00262-014-1609-9
CTLA4 blockade in mesothelioma: finally a competing strategy over cytotoxic/target therapy?
L. Calabrò (2014)
10.1186/2051-1426-1-S1-P87
Combined targeting of co-stimulatory (OX40) and co-inhibitory (CTLA-4) pathways elicits potent effector T cells capable of driving robust anti-tumor immunity
William L. Redmond (2013)
10.1136/jitc-2020-000564
Phase I study of bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in patients with pretreated biliary tract cancer
C. Yoo (2020)
10.1016/j.bbrc.2013.09.031
A DNA vaccine against cytotoxic T-lymphocyte associated antigen-4 (CTLA-4) prevents tumor growth.
K. Lan (2013)
10.7939/R3236S
Designing a point-of-care detection assay for tuberculosis
Susmita Sarkar (2011)
Lipid-based cancer vaccines
Elizabeth A. Vasievich (2011)
10.1007/978-3-662-44946-2_6
Overcoming Cancer Tolerance with Immune Checkpoint Blockade
G. Clifton (2015)
10.4161/onci.27482
Immune checkpoint blockade in malignant mesothelioma
L. Calabrò (2014)
10.1158/1078-0432.CCR-10-2232
Cytotoxic T-Lymphocyte–Associated Antigen-4
A. Salama (2011)
The Tumor Microenvironment as Target for New Cancer Therapies
R. Schwendener (2014)
10.21037/jtd.2017.12.88
New horizons from immunotherapy in malignant pleural mesothelioma.
L. Calabrò (2018)
The effect of ionizing radiation on the homeostasis and functional integrity of murine splenic regulatory T cells
Springer Basel (2012)
10.1158/2159-8290.CD-11-0236
Identification of human regulatory T cells in the setting of T-cell activation and anti-CTLA-4 immunotherapy on the basis of expression of latency-associated peptide.
Jingjing Sun (2012)
10.5167/UZH-102646
A New Approach to Cancer Therapy: The Tumor Microenvironment as Target
R. Schwendener (2014)
10.6004/JADPRO.2014.5.6.3
Immune Checkpoint Blockade: A New Paradigm in Treating Advanced Cancer
Kristen M. Kreamer (2014)
10.1001/jamaoncol.2018.5428
Efficacy and Safety of Avelumab Treatment in Patients With Advanced Unresectable Mesothelioma: Phase 1b Results From the JAVELIN Solid Tumor Trial
R. Hassan (2019)
10.1016/S2213-2600(15)00092-2
Efficacy and safety of an intensified schedule of tremelimumab for chemotherapy-resistant malignant mesothelioma: an open-label, single-arm, phase 2 study.
L. Calabrò (2015)
10.1172/JCI80012
Cytotoxic T lymphocyte antigen-4 and immune checkpoint blockade.
Elizabeth I Buchbinder (2015)
Lymphocyte Composi- tion and Distribution in Inflammatory, Well-differentiated Retroperitoneal Liposarcoma: Clues to a Potential Adaptive Immune Response and Therapeutic Implications
W. Tseng (2012)
Microenvironment and Immunology VISTA Is an Immune Checkpoint Molecule for Human T Cells
J. L. Lines (2014)
10.1186/s12967-016-1070-y
Future perspectives in melanoma research
P. Ascierto (2013)
10.1016/j.cytogfr.2013.01.003
Coinhibitory molecules in cancer biology and therapy.
S. Mocellin (2013)
10.1158/1078-0432.CCR-12-3226
Immunomodulatory Monoclonal Antibodies Combined with Peptide Vaccination Provide Potent Immunotherapy in an Aggressive Murine Neuroblastoma Model
Emily L. Williams (2013)
10.4155/fseb2013.13.86
Case studies of monoclonal antibodies for cancer therapy: technology drives clinical development
A. Lupo (2015)
10.1016/S1470-2045(13)70381-4
Tremelimumab for patients with chemotherapy-resistant advanced malignant mesothelioma: an open-label, single-arm, phase 2 trial.
L. Calabrò (2013)
10.1186/s13058-018-1037-4
Evaluation of anti-PD-1-based therapy against triple-negative breast cancer patient-derived xenograft tumors engrafted in humanized mouse models
R. Rosato (2018)
See more
Semantic Scholar Logo Some data provided by SemanticScholar